Government Unveils Reforms to Medical Device Rules
India's Union Ministry of Health and Family Welfare has introduced targeted amendments to the Medical Devices Rules, 2017, in a move that officials say is designed to promote Ease of Doing Business, eliminate regulatory bottlenecks, and speed up consumer access to advanced healthcare technology. The reforms, announced on August 24, focus on three primary areas: simplifying rules around outsourced sterilisation, standardising laboratory testing fees, and expanding international regulatory recognition.
According to an official statement from the ministry quoted by Lokmat Times, the amendments aim to "simplify regulatory requirements, enhance transparency and facilitate timely access to advanced and innovative medical technologies in the country." The measures are intended to reduce compliance costs, documentation, approval timelines, and associated burdens while maintaining safety, quality, and performance standards.
Outsourcing Sterilisation: Loan Licence Requirement Dropped
A key change comes under Rule 44 of the Medical Devices Rules, which governs outsourced sterilisation. Previously, manufacturers without in-house sterilisation facilities were required to obtain a separate "loan licence" for sterilisation activities even when using a third-party facility that already held a valid licence under the same rules. As explained by a Health Ministry official in The Tribune, this was an additional regulatory requirement that created administrative duplication and increased compliance costs.
Under the amended rules, manufacturers no longer need a separate loan licence when outsourcing sterilisation to a facility that has a valid licence under the Medical Devices Rules, 2017. The change aims to simplify compliance, reduce unnecessary paperwork, and support the ease of doing business, as reported by both The Hindu Business Line and The Tribune. The ministry said in its statement, carried by Lokmat Times, that this simplification would enable manufacturers to more efficiently use specialised sterilisation services, reducing regulatory burden and manufacturing timelines.
To retain accountability, the licence number of the sterilisation facility must be displayed on the device label. Both The Hindu Business Line and The Tribune report that this traceability requirement remains intact, even as the regulatory step is removed. The ministry provided a six-month transition period for manufacturers to update their labelling and packaging, according to reports from ANI, The Hindu Business Line, and other sources.
Uniform Testing Fees Introduced
A further change introduces a Ninth Schedule into the Medical Devices Rules, 2017, prescribing uniform fees for the testing of medical devices by Medical Device Testing Laboratories. As explained by Lokmat Times, this measure establishes a standardised, transparent fee structure across laboratories, reducing ambiguity and variations in testing charges. The Ministry says this will provide greater predictability to manufacturers and importers, minimise disputes, and ensure equitable treatment of stakeholders.
The standardisation is expected to strengthen transparency and efficiency in the regulatory framework. The ministry's statement, as carried by Lokmat Times, notes that the reform will support the sector's predictability without compromising regulatory oversight.
EU Joins Stringent Regulatory Jurisdictions
The third key change expands the list of countries whose regulatory approvals are recognised for waiving clinical investigation requirements in India. Under Rule 63, the previously recognised jurisdictions were the United States, the United Kingdom, Australia, Canada, and Japan. As reported by ANI and The Tribune, the European Union (EU) has now been added to that list.
This decision means that certain medical devices already approved by EU regulators may be exempt from conducting a separate clinical investigation in India, provided they meet India's eligibility conditions. ANI notes that devices lacking predicate devices in India but holding EU approval can now qualify for such waivers. The move is aimed at aligning India's regulatory framework with global standards and reducing cost burdens for importing advanced medical technology, while keeping safety checks intact. The Tribune reported that the change is intended to make the approval process simpler and faster without removing safety measures.
The ministry, through its official statement, described the changes as part of ongoing efforts to align domestic regulations with global benchmarks. ANI reported that the elimination of the loan licence step slashes administrative duplication and compliance costs, particularly benefiting med-tech startups and smaller manufacturers that rely on outsourced sterilisation facilities.
Expected Benefits and Industry Reactions
Across the reports, the unanimous expectation is that these reforms will simplify regulatory compliance, reduce paperwork, and lower associated costs for manufacturers and importers. The focus groups lay on the potential reduction in approval timelines and the speeding up of market entry for innovative devices. The standardised fee structure, meanwhile, aims to inject predictability into the system, easing financial planning for firms.
The changes have been described by officials as part of the government's ongoing commitment to Ease of Doing Business in the healthcare sector. They note that the reformed approach retains essential safety and quality standards while cutting red tape and streamlining procedures.